Int J Cancer:IGF-1/IGFBP-3比率与乳腺癌患者全因死亡风险升高显著相关

2012-08-06 魏冬 医学论坛网

  《国际癌症杂志》(Int J Cancer)近期发表的一项研究表明,血清胰岛素样生长因子1(IGF-1)水平和IGF-1/IGF结合蛋白3(IGFBP-3)比率高与女性乳腺癌患者全因死亡风险升高相关。该结果需要在更大规模乳腺癌癌存活者队列中进行验证。   IGF-1是一种乳腺上皮细胞丝裂原,其在循环中水平升高与乳腺癌进展有关;但是其与乳腺癌患者生存状况的相关性尚未确定。循

  《国际癌症杂志》(Int J Cancer)近期发表的一项研究表明,血清胰岛素样生长因子1(IGF-1)水平和IGF-1/IGF结合蛋白3(IGFBP-3)比率高与女性乳腺癌患者全因死亡风险升高相关。该结果需要在更大规模乳腺癌癌存活者队列中进行验证。

  IGF-1是一种乳腺上皮细胞丝裂原,其在循环中水平升高与乳腺癌进展有关;但是其与乳腺癌患者生存状况的相关性尚未确定。循环中IGF-1浓度由包括IGFBP-3在内的结合蛋白控制,从而可能具有调控IGF-1与乳腺癌转归相关性的作用。

  健康、饮食、运动和生活方式(HEAL)研究是一项关于多种族女性Ⅰ~ⅢA期乳腺癌患者的前瞻性队列研究。研究者对源自该研究的600例患者的血清IGF-1和IGFBP-3浓度进行检测。

  研究者采用Cox比例风险模型评估了IGF-1、IGFBP-3及两者的比率与乳腺癌特异性死亡(42例)和全因死亡(87例)风险的相关性。

  结果显示,在校正了体质指数(BMI)、种族、抽血时他莫西芬使用情况、诊断时治疗情况和IGFBP-3以后,IGF-1最高五分位水平者全因死亡风险升高[危险比(HR)=3.10,95%可信区间(CI)=1.21~7.93,P=0.02]。在一个校正各种因素的模型中,作为游离IGF-1水平一个评估指标的IGF-1/IGFBP-3比率与全因死亡风险升高显著相关(HR=2,95%CI=1.25~6.36,Ptrend=0.01)。

  相关链接:Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A.Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer.Int J Cancer. 2012 Jul 31
 



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648853, encodeId=189c164885304, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Tue May 14 08:19:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039519, encodeId=29da203951977, content=<a href='/topic/show?id=ca1294914d' target=_blank style='color:#2F92EE;'>#IGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9491, encryptionId=ca1294914d, topicName=IGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 12 22:19:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752400, encodeId=1bc11e524007d, content=<a href='/topic/show?id=20829492f8' target=_blank style='color:#2F92EE;'>#IGF-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9492, encryptionId=20829492f8, topicName=IGF-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deaa36532338, createdName=qingrejiedu, createdTime=Thu Jan 17 20:19:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255411, encodeId=e50c12554111c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570886, encodeId=54dd15e08865e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648853, encodeId=189c164885304, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Tue May 14 08:19:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039519, encodeId=29da203951977, content=<a href='/topic/show?id=ca1294914d' target=_blank style='color:#2F92EE;'>#IGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9491, encryptionId=ca1294914d, topicName=IGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 12 22:19:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752400, encodeId=1bc11e524007d, content=<a href='/topic/show?id=20829492f8' target=_blank style='color:#2F92EE;'>#IGF-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9492, encryptionId=20829492f8, topicName=IGF-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deaa36532338, createdName=qingrejiedu, createdTime=Thu Jan 17 20:19:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255411, encodeId=e50c12554111c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570886, encodeId=54dd15e08865e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2013-04-12 xxxx1049
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648853, encodeId=189c164885304, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Tue May 14 08:19:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039519, encodeId=29da203951977, content=<a href='/topic/show?id=ca1294914d' target=_blank style='color:#2F92EE;'>#IGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9491, encryptionId=ca1294914d, topicName=IGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 12 22:19:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752400, encodeId=1bc11e524007d, content=<a href='/topic/show?id=20829492f8' target=_blank style='color:#2F92EE;'>#IGF-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9492, encryptionId=20829492f8, topicName=IGF-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deaa36532338, createdName=qingrejiedu, createdTime=Thu Jan 17 20:19:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255411, encodeId=e50c12554111c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570886, encodeId=54dd15e08865e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
    2013-01-17 qingrejiedu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648853, encodeId=189c164885304, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Tue May 14 08:19:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039519, encodeId=29da203951977, content=<a href='/topic/show?id=ca1294914d' target=_blank style='color:#2F92EE;'>#IGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9491, encryptionId=ca1294914d, topicName=IGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 12 22:19:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752400, encodeId=1bc11e524007d, content=<a href='/topic/show?id=20829492f8' target=_blank style='color:#2F92EE;'>#IGF-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9492, encryptionId=20829492f8, topicName=IGF-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deaa36532338, createdName=qingrejiedu, createdTime=Thu Jan 17 20:19:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255411, encodeId=e50c12554111c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570886, encodeId=54dd15e08865e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648853, encodeId=189c164885304, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Tue May 14 08:19:00 CST 2013, time=2013-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039519, encodeId=29da203951977, content=<a href='/topic/show?id=ca1294914d' target=_blank style='color:#2F92EE;'>#IGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9491, encryptionId=ca1294914d, topicName=IGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 12 22:19:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752400, encodeId=1bc11e524007d, content=<a href='/topic/show?id=20829492f8' target=_blank style='color:#2F92EE;'>#IGF-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9492, encryptionId=20829492f8, topicName=IGF-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deaa36532338, createdName=qingrejiedu, createdTime=Thu Jan 17 20:19:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255411, encodeId=e50c12554111c, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570886, encodeId=54dd15e08865e, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Aug 08 01:19:00 CST 2012, time=2012-08-08, status=1, ipAttribution=)]

相关资讯

IGF-1表达与脑膜瘤细胞增殖活性有关

  最近,石家庄市第三医院神经外科、河北医科大学第二医院的研究人员的一项研究显示, IGF-1表达强度与脑膜瘤细胞增殖活性有关,与增殖细胞核抗原(PCNA)在脑膜瘤的发生、增殖和恶化过程中可能起协同作用,其详细机制有待进一步研究。该研究发表于2012年第1期《脑与神经疾病杂志》。   该研究旨在探讨IGF-1在人脑膜瘤中的表达与脑膜瘤细胞增殖活性之间的关系。   武海龙等研究人员应用